The same study also found that objective response rate is not significantly different between TP53-mutant and wild type, and there is a non-significant trend towards shorter OS on EGFR with TP53 mutation in advanced NSCLC patients who received target therapy (6). The gene discussed is TP53; the disease is non-small cell lung carcinoma.